关于营业收入扣除情况，国发股份回复称，公司2025年预计营收约3.3亿元，扣除与主营业务无关的收 入248.08万元后，营收为3.27亿元。分业务看，医药流通业务收入占比近58%，同比增长4.43%；而司法 IVD与医药制造业务收入分别下降10%和23.44%。 国发股份（600538）2月24日发布公告，回复了上海证券交易所关于其2025年度业绩预告事项的问询 函。上海证券交易所主要关注业绩合规性、流通业务增长及商誉连续减值方面。 | | | | | | 年公司各业务模块预计实现营业收入的金额、占比、毛利率及同比变动情况如下: | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 神 | | | | | | | | | | | | | | | | | 第3页共32页 | | | | | | | | | | | | A T S ST C H TT L D A L A L L P S M M L L B S L L T W S L L T W S L L T W S L L T W S L L T W ...

南方财经2月24日电，国发股份(600538.SH)2026年2月24日公告，回复了上海证券交易所关于其2025年 度业绩预告事项的问询函。交易所主要关注三大问题：业绩构成与合规性、医药流通业务增长合理性， 以及大额商誉减值。关于业绩，问询函要求公司说明营业收入扣除情况。公司回复称，2025年预计营收 约3.3亿元，扣除与主营业务无关的收入248.08万元后，营收为3.27亿元。分业务看，医药流通业务收入 占比近58%，同比增长4.43%；而司法IVD与医药制造业务收入分别下降10%和23.44%。公司前五大客 户在医药流通板块稳定，在司法IVD板块因招投标竞争加剧变动较大，并称不存在收入确认政策变更或 通过新客户实现异常交易的情形。对于医药流通业务收入增长，交易所问询其是否与行业趋势匹配。公 司解释，增长主要源于医院销售，特别是集采品种和麻精药品的销售增加。业务交货以送货上门或快递 为主，以客户签收作为收入确认时点。公司认为其4.43%的增长率，与北部湾区域医药市场约4%-4.5% 的增速及同行业公司表现相符。针对连续大额商誉减值，交易所要求说明减值是否充分。公司披露，其 收购的子公司高盛生物因公安客户预算 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600538 证券简称：国发股份 公告编号：临2026-005 北海国发川山生物股份有限公司 关于上海证券交易所对公司业绩预告相关事项问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司预计2025年度实现营业收入约3.3亿元，扣除与主营业务无关的业务收入和不具备商业实质的营业 收入仍为3.3亿元；归属于母公司所有者的净利润-0.85亿元。请公司补充披露：（1）根据《上海证券交 易所上市公司自律监管指南第2号一一业务办理》附件第七号《财务类退市指标：营业收入扣除》有关 规定，说明营业收入扣除相关情况，包括但不限于扣除项目、金额、相关业务开展情况及扣除原因等， 并逐项核实并说明是否存在其他应当扣除尚无扣除的情况；（2）按主要产品类别或业务板块，列示 2025年度预计实现营业收入的具体金额、占比、毛利率及同比变动情况，并说明主要影响因素；（3） 各业务板块前五大客户情况，包括客户名称、合同签订时间、合作期限、是否新增客户或关联方、销售 内容、销售金额、应 ...

医药流通业务增长与区域市场及行业趋势匹配 北海国发川山生物股份有限公司（以下简称"公司"）近日就上海证券交易所《关于北海国发川山生物股 份有限公司业绩预告相关事项的问询函》发布专项说明公告。公告显示，公司2025年度预计实现营业收 入约3.3亿元，归属于母公司所有者的净利润-0.85亿元，并拟计提商誉减值准备约6244.77万元。天健会 计师事务所对相关财务事项进行了审慎核查，认为公司营业收入扣除合规，医药流通业务增长合理，商 誉减值计提充分。 营业收入扣除合规 医药流通业务成主要增长引擎 根据公告，公司2025年度营业收入32,956.29万元，扣除与主营业务无关的业务收入和不具备商业实质的 营业收入248.08万元后，剩余32,708.21万元。扣除项目主要包括房屋出租、销售废品收入223.54万元及 医药流通贸易业务收入24.54万元（已按净额法调整），占营业收入比重为0.75%。公司表示已对相关业 务及明细进行全面核查，不存在其他应扣未扣情况。 按业务板块划分，医药流通业务2025年实现收入19,072.38万元，占总营收的57.87%，同比增长4.43%， 成为公司收入增长的主要驱动力。该增长主要得 ...

Core Viewpoint - Anhui Wantong Technology Co., Ltd. is facing significant operational challenges, including a projected net loss for 2025, governance changes, and financial adjustments that may impact its future strategy and performance [2][3][4]. Group 1: Performance Overview - The company expects a net loss attributable to shareholders of between 218 million yuan and 368 million yuan for the year 2025, a shift from a profit of 36.92 million yuan in the previous year [2]. - The decline in profitability is attributed to intensified industry competition leading to decreased gross margins, stock incentive expense amortization of approximately 46.11 million yuan, and goodwill impairment provision of 98.41 million yuan related to the acquisition of Huadong Lisheng [2]. Group 2: Governance Structure - On December 31, 2025, the company held its first meeting of the seventh board of directors, electing Chen Xiangwei as chairman and appointing him as general manager, along with key positions such as board secretary and financial officer [3]. - This governance change may influence the company's strategic direction, necessitating close attention to the new management's business plans [3]. Group 3: Financial Activities - The board approved two financial resolutions: adjusting the foreign exchange hedging limit for its wholly-owned subsidiary Yantai Huadong Software Technology Co., Ltd. to a maximum contract value of 90 million yuan per trading day for a period of 12 months, and authorizing the use of up to 500 million yuan of idle funds for cash management in principal-protected financial products [4]. - These measures aim to optimize the efficiency of fund utilization, although the effectiveness of risk control will require ongoing monitoring [4]. Group 4: Stock Performance - On February 6, 2026, the company's stock closed at 9.44 yuan, with a daily increase of 2.05% and a net inflow of 2.31 million yuan from major funds, resulting in a turnover rate of 1.13% [5]. - Short-term fluctuations in fund flow may be influenced by market sentiment or sector rotation, but the company's fundamentals continue to face challenges due to losses [5]. Group 5: Future Development - The key focus areas include the earnings forecast and governance adjustments, with the company currently in a loss position and facing significant goodwill impairment issues [6]. - Important upcoming events include the formal release of the 2025 annual report and potential updates on shareholder reductions or business dynamics [6].

经济观察网 光环新网（300383）近期业绩预告显示2025年预亏超7亿元，主要因计提大额商誉减值；同 时，近期主力资金呈现大幅净流入态势。 业绩经营情况 2026年2月12日，主力资金净流入3.05亿元，股价上涨5.35%，主力净量0.92%，显示资金参与度显著提 升。类似的主力流入事件也发生在2026年2月9日（净流入4.22亿元，股价上涨10.78%）和2026年2月3日 （净流入3.09亿元，股价上涨7.68%）。 以上内容基于公开资料整理，不构成投资建议。 2026年1月26日，光环新网发布2025年全年业绩预告，预计归属净利润亏损7.3亿元至7.8亿元，主要原因 是计提资产减值准备8.9亿元，其中商誉减值占8.65亿元，涉及收购中金云网和光环赞普形成的商誉。该 数据未经审计，最终以年度审计报告为准。 资金动向 ...

百特国际公司(Baxter International Inc.)(NYSE:BAX) 股价暴跌14%，此前这家全球医疗技术领导者公布的第四季度业绩未达分析师预期，并发布了 令人失望的全年盈利指引。 按业务部门划分，医疗产品与疗法销售额增长6%至13.9亿美元，医疗系统与技术增长5%至8.27亿美元，制药业务增长4%至6.68亿美元。 百特最近推出了一种新的运营模式，旨在简化组织结构并提升业绩。Hider补充道："虽然前方的工作需要时间，但我对员工的奉献精神感到鼓 舞，并对百特的长期发展轨迹保持信心。" 公司还宣布了董事会变动，任命Michael R. McDonnell为新董事，而Cathy R. Smith和Stephen H. Rusckowski将于2026年2月13日辞职。 百特股价在财报发布后暴跌，因为投资者对公司业绩不及预期和2026财年疲软的展望做出反应。公司预计2026财年调整后每股收益为1.85至 2.05美元，显著低于分析师共识的2.25美元。 "虽然我们在所有业务部门都实现了销售增长，但我们第四季度的业绩未能达到我们的预期，这凸显了我们专注于推动整个企业持续改进的重要 性，"百特总裁兼 ...

Core Viewpoint - The company, Guangli Technology, is undergoing a minor share reduction by its Vice President Li Zuqing, which is primarily driven by personal financial needs, while the overall market sentiment remains positive due to improving fundamentals [1][2]. Event Impact - Short-term emotional pressure may arise from the executive's share reduction, typically signaling caution regarding company valuation or short-term outlook, potentially leading to retail investor sell-offs. However, the reduction is minimal (0.20%) and does not affect company control or operations [2] - Following the announcement of the reduction plan, the company's stock price increased by 26.47% from January 16 to February 12, with a price fluctuation of 34.63%. On the day of the reduction (February 10), the stock price rebounded by 5.0%, indicating that the market is more focused on fundamental improvements rather than the reduction pressure [2]. Company Fundamentals - The company reported strong performance in the first three quarters of 2025, with revenue of 460 million yuan (+20.75%), net profit attributable to shareholders of 36.52 million yuan (+167.44%), and a gross margin of 54.9% [3]. - For the full year of 2025, the expected net profit is projected to be between 17 million and 24 million yuan, driven by increased semiconductor equipment orders and reduced asset impairments. Institutional forecasts align with this outlook, predicting a net profit of 45 million yuan for 2025, indicating a turnaround from previous losses [4]. Business Transformation Effectiveness - The revenue share from semiconductor packaging and testing equipment has risen to 44.79% in the first half of 2025, with domestic slicing machines receiving orders from leading clients. The safety production monitoring business has a gross margin exceeding 70%, providing stable cash flow [5]. Company Valuation - The current price-to-earnings ratio (TTM) is negative (-441.72) due to losses in 2024, while the price-to-book ratio stands at 7.72, above the industry average. The share reduction may exacerbate the volatility of this high valuation [6]. - As of February 12, 2026, there was a net inflow of 9.79 million yuan in principal funds, indicating that the reduction did not trigger a significant outflow of capital [6]. Future Situation Analysis - The scale of Li Zuqing's reduction plan is limited, and the company's fundamentals continue to improve, particularly in the semiconductor sector, suggesting a positive short-term stock price reaction. However, attention should be paid to the pace of future executive reductions and potential risks related to goodwill impairments [7].

Core Viewpoint - Tianji Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which has led to the company announcing corrections to its financial statements for 2023, 2024, and 2025 [1][3]. Group 1: Regulatory Actions - On February 11, the company received a notice from the CSRC regarding the investigation due to suspected violations of information disclosure laws [3]. - The company is currently conducting its normal business operations, and the investigation is not expected to significantly impact its operations [3]. - The company has also received corrective measures from the Guangdong Regulatory Bureau and warning letters from the Shenzhen Stock Exchange, citing issues such as improper goodwill impairment testing and inaccurate financial accounting [4]. Group 2: Financial Adjustments - The company announced that its board approved corrections and retrospective adjustments to its financial statements for the third quarters of 2023, 2024, and 2025 [3]. - The adjustments will not change the profit or loss nature of previously disclosed reports, nor will they result in negative net assets in the annual financial statements [3]. Group 3: Future Performance Expectations - The company forecasts a turnaround in profitability for 2025, expecting a net profit attributable to shareholders of between 70 million and 105 million yuan, compared to a loss of 1.361 billion yuan in the previous year [5]. - The anticipated improvement in performance is attributed to the rapid growth in demand for electric vehicles and energy storage, along with an increase in sales prices for its main product, lithium hexafluorophosphate, in the fourth quarter of 2025 [5]. - The company’s subsidiary, Changshu New Special Chemical Co., Ltd., is also expected to contribute positively to overall performance due to improved market conditions and increased sales prices for its main product, sodium hypophosphite [5].

财务状况 商誉减值已成为公司业绩的重要扰动因素。截至2024年末，公司商誉账面价值3.32亿元，占总资产 15.77%，未来若医院业务不及预期，可能进一步计提减值，影响盈利稳定性。 业务进展情况 公司业务方面，硫酸阿托品滴眼液III期临床试验已完成受试者入组(2025年05月公告)，但后续审批结果 尚未公布。同时，医药行业受人口老龄化及政策支持，长期前景需关注公司产品创新与渠道建设进展。 经济观察网莎普爱思（603168）发布2025年业绩预亏公告，预计归母净利润亏损2.13亿元至3.19亿元， 主要因对两家医院计提商誉减值准备。同时，公司股东存在减持行为，且近期主力资金流向出现波动。 业绩经营情况 根据莎普爱思2026年01月29日公告，公司预计2025年归母净利润亏损2.13亿元至3.19亿元，主要原因为 对下属两家医院(泰州市妇女儿童医院和青岛视康眼科医院)计提商誉减值准备。此次减值受宏观经济、 行业竞争及政策变化影响。公司2025年前三季度虽实现净利润2763.22万元(同比增长189.85%)，但全年 业绩因减值拖累转亏。 股价与资金表现 股东减持行为持续受到市场关注。例如，2026年01月09日公 ...